FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385693960> ?p ?o ?g. }

• W4385693960 endingPage "2023" @default.
• W4385693960 startingPage "00249" @default.
• W4385693960 abstract "Background Increased serum interleukin (IL)-33 predicts poor outcomes in patients hospitalised with coronavirus disease 2019 (COVID-19). We examined the efficacy and safety of tozorakimab, a monoclonal antibody that neutralises IL-33, in improving outcomes in ACCORD-2 ( EudraCT : 2020-001736-95). Methods ACCORD-2 was an open-label, phase 2a study in adults hospitalised with COVID-19. Patients were randomised 1:1 to tozorakimab 300 mg plus standard of care (SoC) or SoC alone. The primary end-point was time to clinical response (sustained clinical improvement of ≥2 points on the World Health Organization ordinal scale, discharge from hospital or fit for discharge) by day 29. Other end-points included death or respiratory failure, mortality and intensive care unit admission by day 29, and safety. Serum IL-33/soluble stimulated-2 (sST2) complex levels were measured by high-sensitivity immunoassay. Results Efficacy analyses included 97 patients (tozorakimab+SoC, n=53; SoC, n=44). Median time to clinical response did not differ between the tozorakimab and SoC arms (8.0 and 9.5 days, respectively; HR 0.96, 80% CI 0.70–1.31; one-sided p=0.33). Tozorakimab was well tolerated and the OR for risk of death or respiratory failure with treatment versus SoC was 0.55 (80% CI 0.27–1.12; p=0.26), while the OR was 0.31 (80% CI 0.09–1.06) in patents with high baseline serum IL-33/sST2 complex levels. Conclusions Overall, ACCORD-2 results suggest that tozorakimab could be a novel therapy for patients hospitalised with COVID-19, warranting further investigation in confirmatory phase 3 studies." @default.
• W4385693960 created "2023-08-10" @default.
• W4385693960 creator A5009297900 @default.
• W4385693960 creator A5009816171 @default.
• W4385693960 creator A5012228981 @default.
• W4385693960 creator A5013215998 @default.
• W4385693960 creator A5013732481 @default.
• W4385693960 creator A5020099223 @default.
• W4385693960 creator A5021061887 @default.
• W4385693960 creator A5023450211 @default.
• W4385693960 creator A5026193678 @default.
• W4385693960 creator A5027624199 @default.
• W4385693960 creator A5028344690 @default.
• W4385693960 creator A5033934919 @default.
• W4385693960 creator A5037385250 @default.
• W4385693960 creator A5041967602 @default.
• W4385693960 creator A5042548086 @default.
• W4385693960 creator A5056681502 @default.
• W4385693960 creator A5062472986 @default.
• W4385693960 creator A5068917661 @default.
• W4385693960 creator A5072084139 @default.
• W4385693960 creator A5074335409 @default.
• W4385693960 creator A5079358381 @default.
• W4385693960 creator A5084659683 @default.
• W4385693960 creator A5085336912 @default.
• W4385693960 creator A5088572047 @default.
• W4385693960 date "2023-08-09" @default.
• W4385693960 modified "2023-10-04" @default.
• W4385693960 title "A randomised phase 2a study to investigate the effects of blocking IL-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2" @default.
• W4385693960 cites W1490258901 @default.
• W4385693960 cites W2029909301 @default.
• W4385693960 cites W2334624707 @default.
• W4385693960 cites W2729395604 @default.
• W4385693960 cites W2794395525 @default.
• W4385693960 cites W2935954941 @default.
• W4385693960 cites W2989621748 @default.
• W4385693960 cites W3001897055 @default.
• W4385693960 cites W3002108456 @default.
• W4385693960 cites W3016288338 @default.
• W4385693960 cites W3033997257 @default.
• W4385693960 cites W3046375596 @default.
• W4385693960 cites W3088315869 @default.
• W4385693960 cites W3092387456 @default.
• W4385693960 cites W3103134232 @default.
• W4385693960 cites W3111255098 @default.
• W4385693960 cites W3111590711 @default.
• W4385693960 cites W3128070861 @default.
• W4385693960 cites W3134208712 @default.
• W4385693960 cites W3139533040 @default.
• W4385693960 cites W3144413418 @default.
• W4385693960 cites W3171160125 @default.
• W4385693960 cites W3182774911 @default.
• W4385693960 cites W3193750735 @default.
• W4385693960 cites W3202802293 @default.
• W4385693960 cites W3216564062 @default.
• W4385693960 cites W4210642183 @default.
• W4385693960 cites W4213073926 @default.
• W4385693960 cites W4220746352 @default.
• W4385693960 cites W4229028010 @default.
• W4385693960 cites W4283758677 @default.
• W4385693960 cites W4312474460 @default.
• W4385693960 cites W4312920165 @default.
• W4385693960 doi "https://doi.org/10.1183/23120541.00249-2023" @default.
• W4385693960 hasPublicationYear "2023" @default.
• W4385693960 type Work @default.
• W4385693960 citedByCount "0" @default.
• W4385693960 crossrefType "journal-article" @default.
• W4385693960 hasAuthorship W4385693960A5009297900 @default.
• W4385693960 hasAuthorship W4385693960A5009816171 @default.
• W4385693960 hasAuthorship W4385693960A5012228981 @default.
• W4385693960 hasAuthorship W4385693960A5013215998 @default.
• W4385693960 hasAuthorship W4385693960A5013732481 @default.
• W4385693960 hasAuthorship W4385693960A5020099223 @default.
• W4385693960 hasAuthorship W4385693960A5021061887 @default.
• W4385693960 hasAuthorship W4385693960A5023450211 @default.
• W4385693960 hasAuthorship W4385693960A5026193678 @default.
• W4385693960 hasAuthorship W4385693960A5027624199 @default.
• W4385693960 hasAuthorship W4385693960A5028344690 @default.
• W4385693960 hasAuthorship W4385693960A5033934919 @default.
• W4385693960 hasAuthorship W4385693960A5037385250 @default.
• W4385693960 hasAuthorship W4385693960A5041967602 @default.
• W4385693960 hasAuthorship W4385693960A5042548086 @default.
• W4385693960 hasAuthorship W4385693960A5056681502 @default.
• W4385693960 hasAuthorship W4385693960A5062472986 @default.
• W4385693960 hasAuthorship W4385693960A5068917661 @default.
• W4385693960 hasAuthorship W4385693960A5072084139 @default.
• W4385693960 hasAuthorship W4385693960A5074335409 @default.
• W4385693960 hasAuthorship W4385693960A5079358381 @default.
• W4385693960 hasAuthorship W4385693960A5084659683 @default.
• W4385693960 hasAuthorship W4385693960A5085336912 @default.
• W4385693960 hasAuthorship W4385693960A5088572047 @default.
• W4385693960 hasBestOaLocation W43856939601 @default.
• W4385693960 hasConcept C126322002 @default.
• W4385693960 hasConcept C141341695 @default.
• W4385693960 hasConcept C203092338 @default.
• W4385693960 hasConcept C2776376669 @default.
• W4385693960 hasConcept C2779134260 @default.
• W4385693960 hasConcept C3008058167 @default.

• next